DDMAC issues untitled letter concerning Ista journal ad

Share this article:
The FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) issued an untitled letter to Ista Pharmaceuticals concerning a journal advertisement for Vitrase (hyaluonidase injection), indicated for the treatment of vitreous hemorrhage and diabetic retinopathy.
In the letter, DDMAC said the journal ad is false or misleading because it fails to reveal material
facts, thus minimizing the risks associated with treatment with Vitrase. "DDMAC requests that Ista immediately cease the dissemination of violative promotional materials for Vitrase," the letter stated.
A spokesperson for Ista was not immediately available for comment.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions